| dc.contributor.author | Silva, Ana Catarina | |
| dc.contributor.author | Costa, Cláudia Pina | |
| dc.contributor.author | Almeida, Hugo | |
| dc.contributor.author | Moreira, João Nuno | |
| dc.contributor.author | Lobo, José Manuel Sousa | |
| dc.date.accessioned | 2021-04-28T08:52:14Z | |
| dc.date.available | 2021-04-28T08:52:14Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Therapeutic uses of biological medicines are diverse and include active substances from different classes. This chapter provides an overview on the clinical applications of biological medicines containing hormones, blood products, and therapeutic enzymes. Currently, therapeutic hormones have 78 approved medicines, including insulin and analogs, glucagon and analogs, growth hormone, gonadotropins (follicle-stimulating hormone, luteinizing hormone, and human chorionic gonadotropin), thyroid-stimulating hormone, and parathyroid hormone. In contrast, recombinant blood products, and particularly blood factors, anticoagulants, and thrombolytic agents, incorporate 49 approved biological medicines. Regarding recombinant therapeutic enzymes, there are 22 approved medicines. Among the referred biological medicines, there are six biosimilar hormones, and no biosimilars have been approved for recombinant blood products and therapeutic enzymes, which is unexpected.Current investigations on recombinant hormones, recombinant blood products, and therapeutic enzymes seem to follow the same directions, searching for alternative non-injectable administration routes, development of new recombinant molecules with improved pharmacokinetic properties and discovering new clinical applications for approved medicines. These approaches are showing positive results and new medicines are expected to reach clinical approval in the coming years. Future prospects also include the approval of more biosimilar medicines. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.doi | 10.1007/10_2019_111 | pt_PT |
| dc.identifier.isbn | 978-3-030-40464-2 | |
| dc.identifier.uri | http://hdl.handle.net/10284/9810 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.subject | Anticoagulants | pt_PT |
| dc.subject | Blood factors | pt_PT |
| dc.subject | Glucagon | pt_PT |
| dc.subject | Gonadotropins | pt_PT |
| dc.subject | Growth hormone | pt_PT |
| dc.subject | Insulin | pt_PT |
| dc.subject | Therapeutic enzymes | pt_PT |
| dc.subject | Thrombolytic agents | pt_PT |
| dc.title | Hormones, blood products, and therapeutic enzymes | pt_PT |
| dc.type | book part | |
| dspace.entity.type | Publication | |
| oaire.citation.title | Advances in biochemical engineering/biotechnology | pt_PT |
| person.familyName | Silva | |
| person.givenName | Ana Catarina | |
| person.identifier | 953153 | |
| person.identifier.ciencia-id | 5C1D-ED22-0D64 | |
| person.identifier.orcid | 0000-0001-6923-0232 | |
| person.identifier.rid | F-1875-2017 | |
| person.identifier.scopus-author-id | 57028697500 | |
| rcaap.rights | restrictedAccess | pt_PT |
| rcaap.type | bookPart | pt_PT |
| relation.isAuthorOfPublication | 67e7f707-32ec-444a-a20d-a17f8e6e7c21 | |
| relation.isAuthorOfPublication.latestForDiscovery | 67e7f707-32ec-444a-a20d-a17f8e6e7c21 |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Chap. 5__Hormones, Blood Products, and Therapeutic Enzymes.pdf
- Size:
- 637.92 KB
- Format:
- Adobe Portable Document Format